Evaluation the Effect of Ticoplanin in Patients With Coronavirus Disease
Phase 3
Recruiting
- Conditions
- COVID-19.Coronavirus infection, unspecifiedU07.1
- Registration Number
- IRCT20161204031229N3
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Laboratory confirmed COVID-19 with RT-PCR
Laboratory confirmed COVID-19 with lung CT scan
Exclusion Criteria
Chronic kidney Disease
Acute kidney injury
Pregnancy
Breastfeeding
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measurement of inflammatory markers (CRP). Timepoint: at baseline and discharge time. Method of measurement: ELISA.;WBC count. Timepoint: at baseline and discharge time. Method of measurement: Blood count.;Evaluation of lung CT scan. Timepoint: at baseline and discharge time. Method of measurement: Radiologic finding.;Evaluation of inflammatory marker ESR. Timepoint: at baseline and discharge time. Method of measurement: Blood count.
- Secondary Outcome Measures
Name Time Method Body temperature. Timepoint: at baseline and discharge time. Method of measurement: Thermometer.;Fever. Timepoint: at baseline and discharge time. Method of measurement: Thermometer.;Respiratory rate >24/min. Timepoint: at baseline and discharge time. Method of measurement: Counting of respiratory rate in minutes.;Systolic blood pressure <90 mm Hg. Timepoint: at baseline and discharge time. Method of measurement: Manometer.;Oxygen saturation. Timepoint: at baseline and discharge time. Method of measurement: oximeter Pulse.;Pulse rate. Timepoint: at baseline and discharge time. Method of measurement: Counting of pulse rate in minutes.;Level of consciousness or new confusion. Timepoint: at baseline and discharge time. Method of measurement: With glasgow coma scale.